Aeterna Zentaris (AEZS) Tops Q2 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. SPY
4. PTC
5. ATH
6. CME
7. USO
8. AMD
9. EVTL
10. KLC

Go back to Aeterna Zentaris (AEZS) Tops Q2 EPS by 11c

Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results

August 9, 2016 4:30 PM EDT

Near-Term Major Inflection Point Approaching with Expected Completion of two Pivotal Phase 3 Programs in 2016

All $ amounts are in US Dollars

Key developments

Product development programs on track towards FDA submission in 2017 Zoptrex (zoptarelin doxorubicin) pivotal Phase 3 clinical program remains on track for completion in 2016 Macrilen (macimorelin) confirmatory Phase 3 Trial for the evaluation of AGHD also remains on track for completion in 2016 Zoptrex out-licensing activity successfully continues Zoptrex licensee in China and related territories, Sinopharm A-Think... More